{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:31:39Z","timestamp":1793287899255,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s00115-026-02024-8","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:36:21Z","timestamp":1791545781000},"page":"606-614","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-Amyloid-Antik\u00f6rper gegen Alzheimer","Anti-amyloid antibodies against Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"97","author":[{"given":"Timo Jan","family":"Oberstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"2024_CR1","unstructured":"S3-Leitlinie Demenzen, Version\u00a06.1 (AWMF-Registernummer: 038-013). AWMF. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/038-013. Zugegriffen: Juli 2026."},{"issue":"1","key":"2024_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck\u00a0CH, Swanson\u00a0CJ, Aisen\u00a0P et\u00a0al (2023) Lecanemab in Early Alzheimer\u2019s Disease. N Engl J Med 388(1):9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948","journal-title":"N Engl J Med"},{"key":"2024_CR3","unstructured":"Europ\u00e4ische Arzneimittel-Agentur (2025) Fachinformation Lecanemab."},{"issue":"6","key":"2024_CR4","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims\u00a0JR, Zimmer\u00a0JA, Evans\u00a0CD et\u00a0al (2023) Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA 330(6):512\u2013527. https:\/\/doi.org\/10.1001\/jama.2023.13239","journal-title":"JAMA"},{"key":"2024_CR5","unstructured":"Europ\u00e4ische Arzneimittel-Agentur (2026) Fachinformation Donanemab."},{"issue":"4","key":"2024_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2026.100507","volume":"13","author":"R Perry","year":"2026","unstructured":"Perry\u00a0R, Kipps\u00a0C, Soto Martin\u00a0ME et\u00a0al (2026) Lecanemab for treatment of individuals with early Alzheimer\u2019s Disease (AD) who are apolipoprotein E epsilon4 (ApoE epsilon 4) non-carriers or heterozygotes. J\u00a0Prev Alzheimers Dis 13(4):100507. https:\/\/doi.org\/10.1016\/j.tjpad.2026.100507","journal-title":"J Prev Alzheimers Dis"},{"issue":"8","key":"2024_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2026.100605","volume":"13","author":"F Jessen","year":"2026","unstructured":"Jessen\u00a0F, Dell\u2019Agnello\u00a0G, Zimmer\u00a0JA et\u00a0al (2026) Efficacy and safety of donanemab in the European eligible population: TRAILBLAZER-ALZ 2 post-hoc analyses. J\u00a0Prev Alzheimers Dis 13(8):100605. https:\/\/doi.org\/10.1016\/j.tjpad.2026.100605","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"2024_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.14283\/jpad.2022.102","volume":"10","author":"CJ Lansdall","year":"2023","unstructured":"Lansdall\u00a0CJ, McDougall\u00a0F, Butler\u00a0LM et\u00a0al (2023) Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer\u2019s Disease. J\u00a0Prev Alzheimers Dis 10(1):9\u201318. https:\/\/doi.org\/10.14283\/jpad.2022.102","journal-title":"J Prev Alzheimers Dis"},{"issue":"10510","key":"2024_CR9","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/S0140-6736(25)01389-3","volume":"406","author":"GB Frisoni","year":"2025","unstructured":"Frisoni\u00a0GB, Aho\u00a0E, Brayne\u00a0C et\u00a0al (2025) Alzheimer\u2019s disease outlook: controversies and future directions. Lancet 406(10510):1424\u20131442. https:\/\/doi.org\/10.1016\/S0140-6736(25)01389-3","journal-title":"Lancet"},{"issue":"2","key":"2024_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100446","volume":"13","author":"JA Zimmer","year":"2026","unstructured":"Zimmer\u00a0JA, Sims\u00a0JR, Evans\u00a0CD et\u00a0al (2026) Donanemab in early symptomatic Alzheimer\u2019s disease: results from the TRAILBLAZER-ALZ 2 long-term extension. J\u00a0Prev Alzheimers Dis 13(2):100446. https:\/\/doi.org\/10.1016\/j.tjpad.2025.100446","journal-title":"J Prev Alzheimers Dis"},{"key":"2024_CR11","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (2025) Lecanemab \u2013 Nutzenbewertung A25-111. www.iqwig.de. Zugegriffen: .7.2026"},{"key":"2024_CR12","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (2026) Donanemab \u2013 Nutzenbewertung A25-134."},{"key":"2024_CR13","unstructured":"Gemeinsamer Bundesausschuss (2026) Beschl\u00fcsse zur Nutzenbewertung von Lecanemab (Februar 2026) und Donanemab (April 2026). www.g-ba.de. Zugegriffen: .7.2026"},{"issue":"10452","key":"2024_CR14","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","volume":"404","author":"G Livingston","year":"2024","unstructured":"Livingston\u00a0G, Huntley\u00a0J, Liu\u00a0KY et\u00a0al (2024) Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet 404(10452):572\u2013628. https:\/\/doi.org\/10.1016\/S0140-6736(24)01296-0","journal-title":"Lancet"},{"issue":"5","key":"2024_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100150","volume":"12","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici\u00a0GD, Selkoe\u00a0DJ, Schindler\u00a0SE et\u00a0al (2025) Donanemab: Appropriate use recommendations. J\u00a0Prev Alzheimers Dis 12(5):100150. https:\/\/doi.org\/10.1016\/j.tjpad.2025.100150","journal-title":"J Prev Alzheimers Dis"},{"issue":"3","key":"2024_CR16","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings\u00a0J, Apostolova\u00a0L, Rabinovici\u00a0GD et\u00a0al (2023) Lecanemab: Appropriate Use Recommendations. J\u00a0Prev Alzheimers Dis 10(3):362\u2013377. https:\/\/doi.org\/10.14283\/jpad.2023.30","journal-title":"J Prev Alzheimers Dis"},{"issue":"8","key":"2024_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100266","volume":"12","author":"H Wang","year":"2025","unstructured":"Wang\u00a0H, Nery\u00a0ESM, Ardayfio\u00a0P et\u00a0al (2025) The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema\/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6. J\u00a0Prev Alzheimers Dis 12(8):100266. https:\/\/doi.org\/10.1016\/j.tjpad.2025.100266","journal-title":"J Prev Alzheimers Dis"},{"issue":"8","key":"2024_CR18","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack\u00a0CR Jr, Andrews\u00a0JS, Beach\u00a0TG et\u00a0al (2024) Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement 20(8):5143\u20135169. https:\/\/doi.org\/10.1002\/alz.13859","journal-title":"Alzheimers Dement"},{"issue":"15","key":"2024_CR19","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/jama.2024.13855","volume":"332","author":"S Palmqvist","year":"2024","unstructured":"Palmqvist\u00a0S, Tideman\u00a0P, Mattsson-Carlgren\u00a0N et\u00a0al (2024) Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care. JAMA 332(15):1245\u20131257. https:\/\/doi.org\/10.1001\/jama.2024.13855","journal-title":"JAMA"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-026-02024-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-026-02024-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-026-02024-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:38:20Z","timestamp":1793284700000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-026-02024-8"}},"subtitle":["Lecanemab und Donanemab in der Praxis\u00a0\u2013 klinische Bedeutsamkeit, Patientenauswahl und Sicherheitsmanagement","Lecanemab and donanemab in practice\u2014Clinical importance, patient selection and safety management"],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["2024"],"URL":"https:\/\/doi.org\/10.1007\/s00115-026-02024-8","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"29 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"T.J.\u00a0Oberstein\n                      : A.\u00a0Finanzielle Interessen: Drittmittel und geldwerte Leistungen an das Universit\u00e4tsklinikum Erlangen, Verf\u00fcgungsbefugnis als Projektleiter, keine pers\u00f6nlichen Zuwendungen: Siemens Healthineers \u2013\u00a0Forschungskooperation, Personal und Sachmittel, Probenanalytik ohne Berechnung | Noselab\u00a0\u2013 Forschungskooperation, Personal und Sachmittel, Probenanalytik ohne Berechnung | Hummingbird Diagnostics \u2013\u00a0Forschungskooperation, Personal und Sachmittel, Probenanalytik ohne Berechnung | ACCESS-AD Consortium\u00a0\u2013 Beteiligung an einem \u00f6ffentlich gef\u00f6rderten\/IHI-gef\u00f6rderten Verbundvorhaben, Personal- und Sachmittel f\u00fcr die Arbeitspakete WP3 und WP5 | Verg\u00fctung als Pr\u00fcfzentrum f\u00fcr die von Roche gesponserte Studie TRONTIER\u00a02 (Trontinemab). \u2013\u00a0Referentenhonorare von: Lilly | Siemens Healthineers | Eisai | Biogen.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Leiter der Psychiatrischen Institutsambulanz inklusive Ged\u00e4chtnisambulanz der Psychiatrischen und Psychotherapeutischen Klinik (Direktorin Prof. Dr. med. Sarah Kittel-Schneider), Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t (FAU) Erlangen-N\u00fcrnberg Schwabachanlage\u00a06, 91054 Erlangen | Mitgliedschaften: European Alzheimer\u2019s Disease Consortium (EADC) | Deutsches Netzwerk Ged\u00e4chtnisambulanzen (DNG) | Steering Committee des Deutschen Demenzregisters (DEMREG) | ACCESS-AD Konsortium.","order":2,"name":"Ethics","label":"Autorinnen und Autoren","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":3,"name":"Ethics","label":"Wissenschaftliche Leitung","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":4,"name":"Ethics","label":"Der Verlag","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}